1. Interpret the reports and likely problem list
   • Uncontrolled type 2 diabetes
   • Severe hypertriglyceridemia and elevated cardiovascular risk
   • Lower urinary tract symptoms, likely benign prostatic enlargement versus diabetic bladder dysfunction
   • Hypertension with established coronary artery disease/LVH and mild peripheral edema
   • Reported weakness or perceived muscle loss, including medication review
2. Urinary symptoms: diagnostic work-up and treatment
   • Distinguish prostate obstruction from incomplete bladder emptying due to diabetic autonomic neuropathy
   • Tests such as IPSS symptom score, digital rectal examination, PSA when appropriate, post-void residual, ultrasound, uroflowmetry, and urine culture if indicated
   • Medication and referral options
3. Diabetes management
   • Explain why fasting glucose 209 mg/dL and urine glucose 3+ indicate inadequate control
   • HbA1c-based assessment, escalation of glucose-lowering therapy, monitoring, complication screening, nutrition, and activity
4. Lipids and pancreatitis prevention
   • Address triglycerides 596.6 mg/dL, which are severely high and require prompt medical review
   • Identify secondary causes including uncontrolled diabetes and alcohol
   • Pharmacologic and dietary measures to lower triglycerides and prevent pancreatitis
5. Blood-pressure/CAD medication review and edema
   • Assess telmisartan-metoprolol, torsemide/spironolactone (Dytor Plus), aspirin-rosuvastatin, and dapagliflozin in context
   • Discuss whether symptoms may be drug-related, what must not be stopped abruptly, and monitoring of potassium, sodium, renal function, BP, heart status
6. Integrated lifestyle plan and follow-up priorities
   • Alcohol cessation, smoking abstinence, diet, exercise with muscle preservation, home BP/glucose records, and urgent warning signs.

Prioritized diagnostic and treatment plan

Working diagnoses

1. Uncontrolled type 2 diabetes mellitus with symptomatic hyperglycemia
   • Fasting glucose 209.4 mg/dL and urine glucose 3+.
   • Dapagliflozin intentionally increases urinary glucose, but this fasting glucose confirms inadequate systemic glycemic control.
   • Weakness and loss of lean mass may reflect hyperglycemic catabolism, reduced food intake, alcohol-related nutritional issues, or another illness. It needs evaluation.
2. Severe hypertriglyceridemia, likely secondary to uncontrolled diabetes and alcohol use
   • Triglycerides 596.6 mg/dL, total cholesterol 247.6 mg/dL, non-HDL cholesterol 194.7 mg/dL.
   • This requires prompt action to reduce pancreatitis risk and residual atherosclerotic cardiovascular risk.
   • Poorly controlled diabetes, alcohol, high refined-carbohydrate intake, inactivity, and drugs can worsen triglycerides. Severe hypertriglyceridemia is defined at >500 mg/dL, and pancreatitis risk rises particularly as levels exceed 1,000 mg/dL. Goldman-Cecil Medicine, p. 2290.
3. Male lower urinary tract symptoms with possible bladder outlet obstruction
   • Weak stream, hesitancy, incomplete emptying, and frequency suggest benign prostatic hyperplasia (BPH) with bladder outlet obstruction.
   • Important alternative or coexisting diagnosis: diabetic autonomic bladder dysfunction (diabetic cystopathy). It can cause reduced sensation of bladder fullness, poor bladder contraction, increasing post-void residual urine, hesitancy, and recurrent infections. Harrison’s Principles of Internal Medicine, 22nd ed., Genitourinary Dysfunction section.
   • Urinalysis does not suggest UTI: no nitrite, leukocyte esterase, significant pyuria, blood, or bacteria.
4. Hypertension, not at target diastolic pressure
   • BP 130/90 mmHg. Given diabetes and established CAD/LVH, this warrants medication adherence review and individualized optimization, not abrupt substitution.
5. Known CAD/LVH with pedal edema
   • Grade-1 edema and use of a diuretic raise concern for possible fluid retention or underlying heart failure, although this cannot be confirmed without records, examination, ECG, and echocardiography.
6. High ASCVD risk
   • Diabetes, hypertension, previous smoking, dyslipidemia, and reported CAD make secondary prevention essential.

Priority 1: Actions within 24-72 hours

A. Urgent clinical assessment

• Complete inability to pass urine, painful lower abdominal swelling, severe flank pain, fever, or rigors
• Severe epigastric/upper abdominal pain, vomiting, or pain radiating to the back, which can indicate pancreatitis
• Chest pain, worsening breathlessness, fainting, new confusion, or rapidly worsening leg swelling
• Marked dehydration, repeated vomiting, drowsiness, rapid/deep breathing, or glucose persistently >300 mg/dL
• While taking dapagliflozin: nausea, abdominal pain, vomiting, unusual fatigue, or rapid breathing, even if glucose is not extremely high, because this can signal euglycemic ketoacidosis

B. Do not stop current cardiac medicines without clinician review

• Metoprolol, because abrupt withdrawal can provoke tachycardia, angina, or ischemia
• Telmisartan, unless a clinician advises otherwise
• Aspirin and rosuvastatin in a patient with possible CAD
• Diuretic therapy without assessing edema, BP, electrolytes, and heart status

C. Immediate alcohol intervention

Priority 2: Diagnostic work-up at the first visit

1. Diabetes and metabolic evaluation

• HbA1c, preferably urgently
• Fasting plasma glucose and/or structured home glucose record
• Basic metabolic panel: sodium, potassium, bicarbonate, chloride, urea, creatinine, calcium
• Magnesium if on chronic diuretic therapy
• Liver function tests, already normal but repeat if medication changes are planned
• Serum ketones and venous blood gas only if symptomatic or ketones/high anion-gap acidosis are suspected
• Urine albumin-creatinine ratio, even though dipstick urine protein is negative
• Vitamin B12, especially if metformin is started and because alcohol use/nutritional deficiency may contribute to weakness
• Consider vitamin D, creatine kinase, and nutritional assessment if weakness or muscle loss is objective/persistent
• Dilated retinal examination
• Comprehensive foot examination: pulses, monofilament/vibration sensation, skin, ulcers, callus, footwear
• Weight trend and dietary review

2. Lipid evaluation

• Repeat fasting lipid panel after 1-2 weeks of strict alcohol avoidance and dietary change, sooner if clinician prefers
• Direct LDL-C or ApoB, because calculated LDL is unreliable when triglycerides are high
• Consider non-HDL-C and ApoB as practical treatment targets
• Review secondary causes:
  • uncontrolled diabetes
  • alcohol
  • hypothyroidism, though current TSH is normal at 1.079
  • renal or liver disease, currently not evident
  • medication contributors
  • family history of very high triglycerides or pancreatitis

3. Urinary obstruction and prostate/bladder assessment

• International Prostate Symptom Score, IPSS
• Focused abdominal, genital, neurologic, and digital rectal examination
• Post-void residual urine volume by bladder scan, ideally immediately after voiding
• Uroflowmetry
• Renal-bladder ultrasound with prostate volume and assessment for hydronephrosis if residual is elevated, symptoms are severe, or renal function worsens
• PSA after shared decision-making and before starting a 5-alpha-reductase inhibitor, if clinically appropriate
• Urine culture only if fever, dysuria, suprapubic pain, new urgency, or other infection concerns develop
• Urology referral if high residual volume, urinary retention, recurrent infections, hematuria, renal impairment, hydronephrosis, neurologic signs, or failure of initial therapy

4. Cardiac, edema, and antihypertensive review

• Confirm all medications, exact strengths, timing, and adherence by bringing strips/boxes to the visit
• Home BP log: twice daily for 7 days, seated after 5 minutes' rest
• Orthostatic BP and heart rate, given weakness, diuretic use, dapagliflozin, and possible future alpha-blocker use
• ECG
• Echocardiogram if not recently documented, to define LVH, ejection fraction, diastolic function, valve disease, and possible heart failure
• Serum electrolytes and renal function 1-2 weeks after any diuretic, ARB, or mineralocorticoid antagonist adjustment
• Consider NT-proBNP if symptoms or examination suggest heart failure

Priority 3: Treatment plan

A. Glycemic management

Immediate targets

Medication strategy to discuss with endocrinology/internal medicine

1. Continue dapagliflozin only after assessing hydration, urinary status, and sick-day safety
   • It has cardiovascular and renal benefits in appropriate patients.
   • It can increase urinary glucose and urine volume, which may aggravate frequency/nocturia.
   • When combined with a loop diuretic, it can contribute to dehydration or low BP in some patients.
   • It should generally be withheld during prolonged fasting, vomiting/diarrhea, severe illness, dehydration, or before major surgery, under clinician guidance.
2. Start or reintroduce metformin if not contraindicated
   • eGFR is 108 mL/min/1.73 m² and creatinine 0.75 mg/dL, so kidney function does not currently prevent its use.
   • A typical clinician approach is low-dose initiation with food and gradual titration to improve tolerance. Exact selection and dose must be prescribed after confirming no contraindication.
3. Escalate beyond single-agent dapagliflozin
   • His glucose is not controlled on dapagliflozin alone.
   • With established CAD, a GLP-1 receptor agonist with cardiovascular benefit may be considered alongside SGLT2 inhibitor treatment.
   • However, because he reports becoming lean and weak, avoid choosing a weight-loss-promoting drug without discussing nutritional status and the degree of unintended weight loss.
4. Have a low threshold to initiate basal insulin
   • HbA1c is urgently needed.
   • Insulin should be considered if HbA1c is very high, glucose approaches/exceeds 300 mg/dL, symptoms worsen, ketosis develops, or unintentional weight loss/catabolic state is confirmed.
   • The 2026 ADA guidance advises considering insulin with severe hyperglycemia, especially when catabolic features such as weight loss and hypertriglyceridemia are present. It recommends insulin when glucose is ≥300 mg/dL, HbA1c >10%, or symptomatic hyperglycemia is present, as summarized in the ADA pharmacologic guidance.

Glucose monitoring

• Check fasting glucose daily.
• Check 2-hour post-meal glucose several days per week while treatment is adjusted.
• Record glucose, meals, alcohol intake, BP, body weight, urine symptoms, and dizziness.
• Review results within 1-2 weeks, not months.

B. Severe hypertriglyceridemia and ASCVD prevention

Pharmacologic plan for the prescriber

1. Verify rosuvastatin dose and adherence
   • With CAD, diabetes, and very high non-HDL cholesterol, he will usually need high-intensity statin therapy unless contraindicated or not tolerated.
   • Do not stop the statin because triglycerides are high.
2. Add triglyceride-lowering treatment promptly if fasting triglycerides remain ≥500 mg/dL
   • A clinician may use fenofibrate or prescription omega-3 fatty acids to lower triglycerides and reduce pancreatitis risk.
   • If a fibrate is combined with a statin, fenofibrate is generally preferred over gemfibrozil because gemfibrozil has a higher interaction-associated myopathy risk.
   • Monitor renal function, liver enzymes, and muscle symptoms after therapy changes.
3. Reassess direct LDL-C/ApoB after triglycerides improve
   • In established ASCVD, the secondary-prevention LDL-C goal in ADA material is <55 mg/dL. If not achieved on maximally tolerated statin, the cardiologist may consider ezetimibe and then PCSK9-directed therapy depending on actual LDL-C/ApoB and access.

Nutrition for triglycerides

• No alcohol
• Avoid sugar-sweetened drinks, fruit juices, sweets, desserts, white bread, refined rice-heavy meals, bakery foods, and high-fructose products
• Avoid large fatty meals, deep-fried food, ghee/butter-heavy foods, fatty red meat, processed meat, and full-fat dairy
• Choose measured portions of vegetables, pulses/beans, lean chicken/fish, unsweetened low-fat dairy, tofu, eggs, and high-fiber whole foods
• Avoid “bulking” with sugary shakes or alcohol to regain muscle
• Dietitian referral is appropriate

C. Lower urinary tract symptoms

Initial non-drug measures

• Timed voiding every 2-3 hours
• Double voiding: urinate, wait briefly, and try again
• Reduce evening fluids, but do not deliberately dehydrate
• Avoid caffeine and alcohol
• Avoid non-prescribed cold/flu preparations containing decongestants such as pseudoephedrine and antihistamines, which can worsen urinary retention
• Manage constipation
• Improve glucose control, which may reduce osmotic diuresis and urinary frequency

Medication options after residual urine and BP assessment

• If obstruction from BPH is likely and residual urine is acceptable, a clinician may begin an alpha-1 blocker, commonly tamsulosin.
• Because he is already taking telmisartan, metoprolol, diuretic therapy, and dapagliflozin, starting an alpha-blocker may cause dizziness or orthostatic hypotension. Start only with BP review and monitoring.
• If prostate is enlarged, PSA/prostate size supports it, and longer-term progression reduction is needed, a 5-alpha-reductase inhibitor such as finasteride may be considered. It is not an immediate symptom reliever and has sexual and PSA-related implications.
• If post-void residual is high or diabetic bladder dysfunction is suspected, do not simply add bladder-relaxing medication. Urology-directed evaluation is needed because those medicines can worsen retention.

D. Hypertension, edema, and CAD therapy

1. Keep telmisartan as the preferred foundation unless contraindicated
   • It is generally appropriate in diabetes, hypertension, and cardiovascular disease.
   • Assess potassium, creatinine, BP pattern, and adherence before changing it.
2. Review the need and exact composition of “Dytor Plus LS”
   • Bring the package because formulations differ.
   • Diuretic therapy may be necessary for edema/heart failure, but it can worsen dehydration and electrolyte imbalance if over-diuresis occurs, particularly with dapagliflozin.
3. Do not automatically replace metoprolol
   • It may be appropriate for CAD, arrhythmia prevention, angina, or heart failure depending on his true cardiac diagnosis.
   • Fatigue can occur, but uncontrolled diabetes, poor sleep, alcohol, diuretics, and deconditioning are also common explanations.
4. BP target
   • Achieve an individualized BP goal with home readings and orthostatic measurements rather than a single clinic BP. His diastolic BP of 90 mmHg needs follow-up.

Non-pharmacologic treatment plan

Nutrition and muscle preservation

• Dietitian review within 1-2 weeks.
• Protein intake should be individualized. With currently normal kidney function and no documented albuminuria, adequate protein distributed over meals may help preserve lean mass, but this should be coordinated with diabetes and lipid goals.
• Once cardiac stability is confirmed: resistance exercise 2-3 days/week plus regular walking. Start gradually, especially if weakness is significant.
• Avoid intense exercise during acute illness, dehydration, suspected ketosis, or severe uncontrolled glucose.

Smoking

• Continue complete abstinence. He stopped 10 years ago, which is beneficial.

Alcohol

• Complete cessation is a key component of treatment, not an optional lifestyle suggestion, given triglycerides >500 mg/dL and diabetes.

Vaccination and preventive care

• Review influenza, pneumococcal, hepatitis B, and COVID vaccination status.
• Annual dental, retinal, kidney, and foot screening.

Follow-up schedule

Key clinical interpretation

Add one GLP-1 medicine: Semaglutide

Before starting semaglutide

1. Check HbA1c, current weight trend, dietary intake, and hydration status.
2. Ensure there is no current pancreatitis. With triglycerides 596.6 mg/dL and alcohol exposure, he is already at increased pancreatitis risk. Treat triglycerides and stop alcohol urgently.
3. Ask about personal/family history of medullary thyroid carcinoma or MEN2. Semaglutide is contraindicated if present.
4. Arrange/confirm a diabetic retinal exam, particularly if there is known retinopathy, because rapid glucose improvement can transiently worsen retinopathy.
5. Review nausea, vomiting, severe reflux, gastroparesis, or poor appetite. Do not use it during significant vomiting/dehydration.
6. Do not start if he currently has severe abdominal pain, persistent vomiting, or pain radiating to the back. Evaluate for pancreatitis first.

Counseling and monitoring

• Continue dapagliflozin 10 mg daily only if well hydrated and not acutely ill, unless the prescriber changes it.
• Semaglutide and dapagliflozin can be used together, but monitor for reduced intake, dehydration, dizziness, and worsening urinary frequency.
• Common adverse effects: nausea, early fullness, reflux, constipation, diarrhea, and reduced appetite. Eating smaller, lower-fat meals and slow dose escalation helps.
• Stop the drug and seek urgent medical assessment for persistent severe upper abdominal pain, especially with vomiting or pain radiating to the back. The FDA prescribing information warns to discontinue semaglutide if pancreatitis is suspected.
• Because he already reports muscle loss or weakness, monitor body weight, appetite, protein intake, and strength. Avoid unplanned rapid weight loss. Resistance exercise and adequate protein intake should be part of the plan once clinically stable.